About Miragen Therapeutics, Inc.

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

At the moment the company generates 9M USD in revenues.

On its last earning announcement, the company reported a loss of -1.04$ per share.

The book value per share is 2.23$

Miragen Therapeutics, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
9M - -29M -318.39% -29M -1.04 - - 27M 2.23 -26M - -26M